TOP PICK
In-home, non-invasive respiratory devices. Grows organically and by acquisition. Earnings beat for second consecutive quarter. Awesome management. Growing phenomenally, projected 25% topline growth over next year. Profitable, big cash balance, buying back stock. Discount to peers. NASDAQ listing should generate interest. (Analysts’ price target is $15.01)
0
TOP PICK
Seeing an increase with in-person shopping and dining. Helps businesses be more efficient. Continues to ramp up revenue numbers. Company is anticipating EBITDA-positive 18 months from now. Strong technically and fundamentally. No dividend.
0